Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783347 | 0.80 | TP53 (0.48) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31612432 | 0.78 | TP53 (0.46) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| SCHEMBL1544963 | 0.78 | PTGDR2 (0.36) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| SCHEMBL9938159 | 0.76 | PGK1 (0.36) | ALDH1A1PTGDR2PGK1CYP2A6AHR | |
| SCHEMBL12872214 | 0.76 | PTGDR2 (0.39) | TP53TDP1CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL3227489 | 0.76 | TP53 (0.33) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| SCHEMBL11902651 | 0.76 | CYP3A4 (0.52) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| SCHEMBL2809328 | 0.76 | HSD17B10 (0.50) | TSHRTDP1CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL2809814 | 0.76 | ALDH1A1 (0.52) | TP53TSHRTDP1CYP3A4ALDH1A1 | |
| SCHEMBL28352216 | 0.76 | PYCR1 (0.39) | TP53TSHRTDP1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108101740-B | Method for directly converting aromatic alkyne into chiral alcohol by one-pot method | 三峡大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-108101741-B | Method for synthesizing chiral alcohol by alkyne hydration/asymmetric hydrogenation tandem | 三峡大学 | 2021-06-29 | — | — | CN | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| EP-2718284-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| US-8445141-B2 | Sulfonic acid group-containing polymer, method for producing the same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/electrode assembly, and fuel cell | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2013-05-21 | — | — | US | disclosed |
| US-8216727-B2 | Aromatic hydrocarbon based proton exchange membrane and direct methanol fuel cell using same | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20120052411-A9 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20090075147-A1 | Sulfonic acid group-containing polymer, method for producing the same, resin composition containing such sulfonic acid group-containing polymer, polymer electrolyte membrane, polymer electrolyte membrane/electrode assembly, and fuel cell | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1889863-A1 | SULFONIC ACID GROUP-CONTAINING POLYMER, METHOD FOR PRODUCING SAME, RESIN COMPOSITION CONTAINING SUCH SULFONIC ACID GROUP-CONTAINING POLYMER, POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE/ELECTRODE ASSEMBLY, AND FUEL CELL | Toyo Boseki Kabushiki Kasisha (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070207361-A1 | AROMATIC HYDROCARBON BASED PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1826846-A1 | AROMATIC HYDROCARBON-BASE PROTON EXCHANGE MEMBRANE AND DIRECT METHANOL FUEL CELL USING SAME | Toyo Boseki Kabushiki Kasisha (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | TP53 4145/4885TSHR 2179/4885TDP1 505/4885 |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | TP53 4145/4885TSHR 2179/4885TDP1 505/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | TP53 4145/4885TSHR 2179/4885TDP1 505/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | TP53 4145/4885TSHR 2179/4885TDP1 505/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | TP53 4145/4885TSHR 2179/4885TDP1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.